Deals
Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Allergan released its third-quarter financials, with mixed results and plans to make fairly major changes.
Shares of Halyard Health are up more than 12 percent after the company announced it was selling its S&IP business to Owens & Minor for $710M.
The Crestwood, KY-based company plans to raise $150M by offering 10.7 million shares at a price range of $13 to $15.
Investors and analysts are wondering if the company should buy a biotech to bolster its pipeline and bottom line.
Fosun Pharma said it would buy Tridem Pharma S.A.S. for $73M, in a move to expand its market share in Europe and Africa.
As part of consolidation program, Shire is looking to sell a manufacturing facility in Milford, MA that it gained through its 2015 acquisition of Baxalta.
Fresh off the heels of its CAR-T approval, Novartis expanded its oncological arsenal with a $3.9B acquisition of Advanced Accelerator Applications.
Merck released its third-quarter financial results today, and along with it a hint--just a hint--that there might be some M&A deals in the future.
Siemens AG is looking to take its Healthineers unit public.
Shares of Neos Therapeutics have soared more than 38 percent this morning after PDL BioPharma announced its intention to acquire the company in an all-cash deal that could total about $287M.